Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RapCo-19

Financiado

Cerrado

Rapid COVID 19 Passive Therapy Response Platform

The SARS-CoV-2 pandemic requires the most serious and rapid healthcare response seen in modern history. The lag time between the emergence of the pathogen and the implementation of a licensed vaccine still remains an obstacle for... ver más

31/05/2022

REMEDY BIOLOGICS L...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

REMEDY BIOLOGICS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-05-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 56% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

REMEDY BIOLOGICS LIMITED

2.50M€ | Lider

MOLDEADOS TECNICOS PLASTICOS

527.60K€ | Participante

SMR AUTOMOTIVE SYSTEMS SPAIN

536.61K€ | Participante

Proyectos interesantes

CoroNAb

Medical Technol...

Nanotechnology

3M€ Cerrado

PDC2021-120759-I00

Medical Technol...

Nanotechnology

132K€ Cerrado

CPP2021-008348

Medical Technol...

Materials Scien...

358K€ Cerrado

PRE2021-099271

Medical Technol...

Pharmaceutical...

101K€ Cerrado

PID2020-117145RB-I00

Medical Technol...

Pharmaceutical...

303K€ Cerrado

SAF2015-71714-R

Medical Technol...

Nanotechnology

145K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 22 meses Fecha Inicio: 2020-07-28
Fecha Fin: 2022-05-31

Líder del proyecto

REMEDY BIOLOGICS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The SARS-CoV-2 pandemic requires the most serious and rapid healthcare response seen in modern history. The lag time between the emergence of the pathogen and the implementation of a licensed vaccine still remains an obstacle for prophylactic measures. In addition, how long immunity lasts for following COVID-19 infection is a big unknown. The development of immunity to the currently circulating SARS-CoV2 may not provide sterilising protection against subsequent coronavirus infections. If this were to be confirmed, it would add to the challenge of managing the pandemic. Short-lived passive immunisation with an anti-COVID-19 therapy is immediately required to treat infected patients and to ‘flatten the infection curve’ and to provide time for ‘herd immunity’ approaches. Devising an effective strategy requires an approach that is designed to exploit the extreme heterogeneity of the human anti-viral immune response. RemedyBio’s Nanoreactor technology is such a system. It is the result of a 5-year research programme to develop a platform to rapidly and simultaneously analyse millions of single antibody-producing immune cells from an individual sample. In the context of COVID-19, this presents an opportunity to rapidly identify the best antibodies from the immune systems of COVID-19 convalescent patients from which to create a rapid passive therapeutic for those that are critically ill from the virus. Based on records from 1918/1919, it is plausible for the COVID-19 pandemic to wane in the late spring (in Europe), and come back as a second wave in the winter, which, as was the case in 1918, could be even worse than what we're facing now. COVID-19 is a global health problem and we need to be ready for this. This project is designed to combine novel discovery and delivery technologies to form a platform to rapidly identify, produce and deliver anti-viral neutralising antibodies to COVID-19.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores